BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25800719)

  • 1. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
    Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
    Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
    Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
    Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
    Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
    Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of HER2 gene amplification and protein expression in gastric cancer.
    Yan B; Yau EX; Bte Omar SS; Ong CW; Pang B; Yeoh KG; Salto-Tellez M
    J Clin Pathol; 2010 Sep; 63(9):839-42. PubMed ID: 20696687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
    van der Vegt B; de Bock GH; Bart J; Zwartjes NG; Wesseling J
    Mod Pathol; 2009 Jul; 22(7):879-86. PubMed ID: 19305385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.